Core Viewpoint - Quantum BioPharma Ltd. is set to host a Business Update Conference Call on May 6, 2025, to discuss its year-end financial results, regulatory initiatives, commercial-readiness activities, and anticipated milestones [1][2]. Group 1: Conference Call Details - The conference call will be led by CEO Zeeshan Saeed and Head of Finance and M&A Jason Sawyer, followed by a Q&A session [2]. - The call is scheduled for May 6, 2025, at 4:30 p.m. Eastern time, with dial-in and webcast access provided [2]. - A telephone replay will be available approximately three hours after the call and will run until August 6, 2025 [2]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [3]. - The company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation associated with multiple sclerosis, showing promise in preclinical models [3]. - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition, which markets the unbuzzd™ product, and is entitled to a 7% royalty on sales until reaching $250 million, after which the royalty will decrease to 3% [3].

Core Viewpoint - Quantum BioPharma Ltd. has appointed Kevin Malone as an advisor to the Board of Directors, leveraging his extensive experience in wealth management and stock trading, particularly in combating market manipulation [1][5]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, including multiple sclerosis (MS) [7]. - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation, a key factor in MS, and is currently in preclinical development [7]. - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition Corp., which markets the product unbuzzd™, and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the royalty rate will drop to 3% [7]. Kevin Malone's Background - Kevin Malone has over 40 years of experience in wealth management and launched Malone Wealth in 2021, focusing on pattern recognition and data research [2]. - His investment philosophy emphasizes rigorous research, disciplined risk management, and a long-term approach to maximize returns while minimizing risk [3]. - Malone is committed to fighting market corruption and has initiated a charitable fund aimed at improving financial literacy in the U.S. public education system [4]. Strategic Importance of Malone's Appointment - The CEO of Quantum BioPharma, Zeeshan Saeed, expressed enthusiasm about Malone's expertise, particularly in naked short squeeze strategies, which will enhance the company's efforts against market manipulation [5]. - Malone's personal experiences with market corruption, including the GameStop incident in 2021, have motivated him to become a fiduciary dedicated to combating such practices [6].

Core Viewpoint - Quantum BioPharma Ltd. has successfully dismissed a reconsideration motion by Dr. Raza Bokhari, affirming the company's position in a legal dispute regarding his termination as CEO [1][2]. Legal Proceedings - Dr. Raza Bokhari's claim of wrongful dismissal was dismissed by Arbitrator Cunningham, resulting in Quantum BioPharma being awarded approximately CAD $2.81 million in arbitration costs plus interest [2]. - The Court of Appeal awarded an additional CAD $180,000 in costs related to Dr. Bokhari's failed motion for leave to appeal [2]. - Quantum BioPharma has initiated a Petition to Confirm Arbitration Award in the U.S. District Court to collect the awarded amounts from Dr. Bokhari, which includes various monetary judgments totaling USD $147,301.04 and CAD $2,814,229.15, among others [3]. Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [4]. - The company is advancing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [4]. - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition Corp., which markets the product UNBUZZD™, and is entitled to a 7% royalty on sales until reaching CAD $250 million, after which the royalty rate will decrease to 3% [4].

TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), today announced its licensee – Celly Nutrition Corporation ("Celly Nutrition"), the company behind unbuzzd™ – the beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms – has secured a landmark partnership with the Asian American Trade Associations Council ("AATAC") to expand the retail availability of unbuzzd™, increase ...

Core Viewpoint - Quantum BioPharma Ltd. announced the launch of its anti-hangover beverage, unbuzzd, in Puerto Rico through its licensee Celly Nutrition and distribution partner FUSION Distribution Group, aiming to expand its market presence in the Caribbean region [1][5]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on innovative solutions for neurodegenerative and metabolic disorders, including alcohol misuse [11]. - Celly Nutrition Corporation is a public issuer specializing in wellness and recovery supplements, with unbuzzd developed by a team in pharmacology and medicine [7]. - FUSION Distribution Group is a leading distributor of health-conscious food and beverages in Puerto Rico and the Caribbean, with a strong network including major retailers [4][6]. Product Details - unbuzzd is designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms, supported by a double-blind placebo-controlled study [3][8]. - The product is available in convenient "On-the-Go Powder Stick Packs" and can be purchased in various pack sizes [9]. Distribution Strategy - FUSION will distribute unbuzzd across various retail channels in Puerto Rico, including grocery stores, pharmacies, and hospitality venues, aiming for widespread consumer accessibility [5][4]. - The partnership with FUSION is seen as a significant milestone for Celly Nutrition in expanding unbuzzd's retail availability [5]. Financial Arrangement - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition and will receive a 7% royalty on unbuzzd sales until reaching $250 million, after which the royalty will decrease to 3% [11].

"We are very excited about the potential of this novel PET biomarker to directly visualize and measure demyelination in the central nervous system", said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma. "We expect that this biomarker will be an important diagnostic tool in future MS trials investigating therapies that can prevent demyelination and promote remyelination. This is very relevant to our Lucid-MS clinical development program as Lucid-MS has been shown ...

EXHIBIT 99.1 Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company") is pleased to announce that it has closed the final tranche ("Final Tranche") of the offering announced on December 5, 2024 (the "December 5 NR") as amended on January 20, 2025, and based on the better terms announced on March 7, 2025 (the ...

TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company") is pleased to announce that it has closed the final tranche ("Final Tranche") of the offering announced on December 5, 2024 (the "December 5 NR") as amended on January 20, 2025, and based on the better terms announced on March 7, 2025 (the "March 7 NR"). The Company issued 2,420 Debenture Units (as defined in the December 5 NR, as amended by the March 7 NR) for $2,42 ...

Financial Performance - The company reported its financial results for the fiscal year ended December 31, 2024, with detailed analysis available in the 2024 Annual MD&A[514]. - No significant trends or uncertainties are expected to adversely affect net revenues or profitability for the period from January 1, 2024, to December 31, 2024[517]. - The total cumulative return for Quantum BioPharma Ltd. was C$3.63 as of December 31, 2024, compared to C$100 on December 31, 2020, indicating a significant decline in shareholder value over the period[559]. Executive Leadership - The company’s executive team includes Anthony Durkacz as Co-Executive Chairman and Zeeshan Saeed as CEO, with a focus on strategic leadership[520]. - Donal Carroll resumed the role of CFO on August 30, 2024, after previously serving in various financial leadership roles[527]. - The company has not disclosed any new products or technologies in the current report, but ongoing R&D efforts are highlighted[516]. Compensation and Governance - The company has a compensation philosophy aimed at aligning executive pay with performance, with specific disclosures for NEOs for the year ended December 31, 2024[538]. - The executive compensation program for the year ended December 31, 2024, included base compensation, potential annual incentive awards, Options, RSUs, and PSUs[541]. - For 2024, Zeeshan Saeed, CEO, received a total compensation of $583,685, which included a salary of $218,635 and share-based awards of $365,050[563]. - The Compensation, Nominating and Governance Committee evaluates executive performance against the Company's goals and compares it with other similar-sized reporting issuers[546]. - The Company aims to provide a competitive compensation package to attract and retain qualified executives while linking compensation to corporate performance[543]. - The Company does not have fixed criteria for determining compensation, opting instead for a contextual analysis based on various factors[547]. - The Board believes that the compensation levels for directors and executive officers should not be directly compared to market performance due to external factors affecting stock prices[559]. Board Structure and Responsibilities - The company’s board includes members with extensive experience in healthcare, finance, and strategic management, enhancing its governance[520][529]. - There are no family relationships among the executive officers or directors, ensuring a professional governance structure[536]. - The Board consists of seven members, with four being independent directors[598][599]. - The Board is responsible for overseeing the development of the Company's strategic plan and ensuring management meets corporate objectives[595]. - The Board has adopted a Code of Conduct and Ethics to guide ethical business conduct and compliance with applicable laws[617]. - The Board's mandate includes assessing the effectiveness of its committees and individual directors[607]. - The Compensation, Nominating and Governance Committee is responsible for recommending candidates for Board nomination and ensuring the Board's effectiveness[640][641]. Employee Relations and Workforce - As of December 31, 2024, the company had seven full-time employees, a decrease from 17 in 2022, with research and development staff reduced from 12 to 2[655][656]. - The company maintains good relations with its employees, with no employees represented by collective bargaining agreements[655]. - The company does not have any women on the Board or in executive officer positions, representing 0%[654]. - The company has not adopted a term limit for directors, considering the benefits of renewal in the context of the Board's needs[649]. - The company does not have specific targets for appointing women to the Board or in executive officer positions[653]. Risk Management - The company operates primarily in Canada, the United States, and Australia, exposing it to foreign currency risk without using financial derivative instruments to manage this risk[797]. - The company holds certain cryptocurrency assets, which exposes it to significant volatility and regulatory risks in the cryptocurrency markets[799]. Audit and Compliance - The Audit Committee meets quarterly to review and approve the unaudited interim and annual audited financial statements, ensuring management fulfills its financial reporting responsibilities[627][628]. - The Audit Committee pre-approved all audit services provided by independent auditors for the fiscal year ended December 31, 2024[637]. - The company established a 401(k) plan on January 31, 2021, which was terminated on December 31, 2021, and currently has no pension plans[579]. - The annual cost for directors' and officers' liability insurance was C$108,000 for the year ended December 31, 2024[588]. - Each director is entitled to an annual retainer of C$50,000, which can be paid in cash, share-based compensation, or a combination of both[591].

Core Insights - Quantum BioPharma Ltd. has reported significant advancements in its clinical trials and financial performance for the year ended December 31, 2024, including the completion of the unbuzzd™ clinical trial and progress in the Lucid-21-302 Phase 1 trial for multiple sclerosis [1][12][14] Financial Performance - The company reported cash and cash equivalents of $12.1 million USD as of December 31, 2024, an increase from $11.1 million USD in 2023 [3] - Operating expenses were reduced to $16.1 million USD in 2024, down from $23.8 million USD in 2023, marking an improvement of over 32% [3] - Net cash used in operations decreased to $6.9 million USD in 2024 from $10.8 million USD in 2023, reflecting a 36% improvement [4] - The net loss for the year was $14.9 million USD, an 18% improvement compared to a net loss of $18.2 million USD in 2023 [6] Clinical Developments - The unbuzzd™ clinical trial demonstrated that the product significantly accelerated the reduction of Blood Alcohol Concentration (BAC) by over 40% faster within 30 minutes compared to control subjects, while also alleviating symptoms of intoxication and hangover [9][13] - The company has initiated the development of rekvry™, a treatment for alcohol misuse, aimed at addressing unmet healthcare needs [8] - The Lucid-21-302 drug for multiple sclerosis has completed a Phase 1 trial, showing safety and tolerability, and is preparing for a Phase 2 trial [14][16] Strategic Initiatives - Celly Nutrition Corp., the licensee for unbuzzd™, is exploring an initial public offering (IPO) and has engaged a New York investment bank to raise up to $10 million USD [9][15] - The company has diversified its treasury by purchasing $3.5 million worth of Bitcoin and other cryptocurrencies, reflecting a strategic approach to enhance liquidity [16][17] - Quantum BioPharma is focused on expanding the distribution of unbuzzd™ through partnerships and e-commerce initiatives [18]